

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1 (Previously Presented): An immunogen derived from a protein allergen, comprising

a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping;

b) a polymeric form of said fragment, in which form the fragment constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker; or

c) a non-anaphylactic recombinant polymeric form of said protein allergen having 2 to 10 monomeric units in which the protein allergen constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker.

Claim 2 (Previously Presented): The immunogen according to claim 1, wherein the polymeric form of said fragment is recombinantly produced.

Claim 3 (Canceled).

Claim 4 (Previously Presented): The immunogen according to claim 1 or 2, wherein said immunogen also contains a carrier for the fragment in (a) and the polymeric forms in (b) and (c), respectively.

Claim 5 (Canceled).

Claim 6 (Previously Presented): The immunogen according to claim 1 or 2, wherein said immunogen is according to (b) or (c).

Claims 7-20 (Canceled).

Claim 21 (Currently Amended): The immunogen of claim ~~3~~ 1, wherein said immunogen is according to (b) or (c) and said oligopeptide linker comprises 1-30 amino acid residues.

Claim 22 (Previously Presented): The immunogen of claim 21, wherein said amino acid residues are hydrophilic.

Claims 23-24 (Canceled).

Claim 25 (Currently Amended): The immunogen according to claim ~~4~~ 28, wherein the fragment comprises SEQ ID NO:19.

Claim 26 (Currently Amended): The immunogen according to claim 1 28, wherein the fragment comprises SEQ ID NO:20.

Claim 27 (Currently Amended): The immunogen according to claim 1 28, wherein the fragment comprises SEQ ID NO:21.

Claim 28 (New): An immunogen derived from Bet v 1 protein allergen, comprising

a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping;

b) a polymeric form of said fragment, in which form the fragment constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker; or

c) a non-anaphylactic recombinant polymeric form of said protein allergen having 2 to 10 monomeric units in which the protein allergen constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker.

Claim 29 (New): The immunogen according to claim 28, wherein the polymeric form of said fragment is recombinantly produced.

Claim 30 (New): The immunogen of claim 28, wherein said immunogen is according to (b) or (c) and said oligopeptide linker comprises 1-30 amino acid residues.

Application No. 09/897,042
Amendment dated October 20, 2003
Reply to Office Action of May 19, 2003

Claim 31 (New): The immunogen of claim 30, wherein said amino acid residues are hydrophilic.